200 related articles for article (PubMed ID: 23298113)
1. Dosimetry in differentiated thyroid carcinoma (12-1402R).
Minguez P; Genolla J; Celeiro JJ; Fombellida JC
Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
[TBL] [Abstract][Full Text] [Related]
2. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
3. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279. PubMed ID: 27782699
[TBL] [Abstract][Full Text] [Related]
4. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.
Flux GD; Haq M; Chittenden SJ; Buckley S; Hindorf C; Newbold K; Harmer CL
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):270-5. PubMed ID: 19760413
[TBL] [Abstract][Full Text] [Related]
5. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
6. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
7. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
9. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.
Pilli T; Brianzoni E; Capoccetti F; Castagna MG; Fattori S; Poggiu A; Rossi G; Ferretti F; Guarino E; Burroni L; Vattimo A; Cipri C; Pacini F
J Clin Endocrinol Metab; 2007 Sep; 92(9):3542-6. PubMed ID: 17609306
[TBL] [Abstract][Full Text] [Related]
10. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
12. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.
Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM
Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171
[TBL] [Abstract][Full Text] [Related]
13. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
14. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
15. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
16. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
18. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
19. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
